Cardiac Marker Testing Market 5.4% CAGR: Top Companies in 2026 According to a newly published market research report by 24LifeSciences, global cardiac marker testing market was valued at USD 2.54 billion in 2024 and is projected to reach USD 3.65 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.4% during the forecast period 2025–2031. Cardiac marker testing involves the measurement of specific biomarkers released into the bloodstream during cardiac distress, such as a myocardial infarction (heart attack) or heart failure. These tests are crucial for the rapid and accurate diagnosis, risk stratification, and management of patients presenting with acute coronary syndrome (ACS). Key biomarkers measured include troponins (I and T), creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP) or its precursor, NT-proBNP. Their established efficacy in providing critical diagnostic information continues to underpin their importance in emergency medicine, cardiology, and intensive care settings. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9094/cardiac-marker-testing-market